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Abstract
As the field of molecular imaging evolves and increasingly is asked to fill the discovery and validation space between basic
science and clinical applications, careful consideration should be given to the models in which studies are conducted. The
MIN-O mouse model series is an established in vivo model of human mammary precancer ductal carcinoma in situ with
progression to invasive carcinoma. This series of transplant lines is propagated in vivo and experiments utilizing this model
can be completed in non-engineered immune intact FVB/n wild type mice thereby modeling the tumor microenvironment
with biological relevance superior to traditional tumor cell xenografts. Unfortunately, the same qualities that make this and
many other transplant lines more biologically relevant than standard cell lines for molecular imaging studies present
a significant obstacle as somatic genetic re-engineering modifications common to many imaging applications can be
technically challenging. Here, we describe a protocol for the efficient lentiviral transduction of cell slurries derived from
precancerous MIN-O lesions, in vitro culture of ‘‘MIN-O-spheres’’ derived from single cell clones, and the subsequent
transplantation of these spheres to produce transduced sublines suitable for optical imaging applications. These lines retain
the physiologic and pathologic properties, including multilineage differentiation, and complex microanatomic interaction
with the host stroma characteristic of the MIN-O model. We also present the in vivo imaging and immunohistochemical
analysis of serial transplantation of one such subline and detail the progressive multifocal loss of the transgene in successive
generations.
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Introduction
Ductal Carcinoma in situ (DCIS) is the term given to those
cancers which demonstrate marked atypia, but are non-invasive.
While DCIS without associated invasive breast cancer (IBC) is
rarely detected as a palpable lump, it is estimated to account for
approximately 20–30% of those cancers found in mammography
screening programs [1,2]. It can be expected that as mammog-
raphy screening in developing countries becomes more common,
so too will the diagnosis of DCIS. While DCIS itself is not
generally life-threatening, it is associated with an increased risk of
IBC. Conventional wisdom regarding the progression of breast
cancer from atypical ductal hyperplasia to DCIS to IBC has
recently come into question [3]. However, studies examining the
relationship between DCIS, IBC and the molecular pathways that
link them, while most definitely needed to enhance treatment of
patients showing DCIS, remain underrepresented in the literature.
In order to address this deficiency, we have developed and
extensively characterized a mouse mammary intraepithelial neo-
plasia (MIN) that accurately models human DCIS and progresses
to invasive carcinoma. The mouse MIN and the outgrowths
derived from their transplantation (MIN-O) satisfy the classic
operational definition of premalignancy [4,5]. Each of the six
MIN-O lines that we developed meets the following trans-
plantation criteria: grows in gland-cleared fat pad (orthotopic);
does not grow in the subcutis (ectopic); does not senesce over many
generations of transplantation; and consistently transforms to
a phenotype characterized by an ability to grow in the subcutis
(ectopic). The biological transplantability and reproducibility of
MIN-O permit accurate experiment-based in vivo/ex vivo correla-
tions [6,7,8] that are not possible in existing xenograft models or in
mouse models based on whole mammary glands. These trans-
plantable precancerous MIN-O lines are clonal and have unique
morphological and biological characteristics modeling human
tissue heterogeneity. Their biological predictability has allowed
detailed biological and molecular analyses of transitions from
normal to premalignant to malignant and to metastatic states
[6,8,9,10,11]. MIN outgrowths (MIN-O) are easily expandable
and amenable to experimental manipulation and the in vivo
mammary fat pad provides an ideal microenvironment in which to
study the complexities of tumor progression. In addition to
transplanting and expanding small pieces of MIN tissue for
outgrowth, we have shown that MIN-O can arise in a gland-
cleared fat pad from a transplanted multicellular sphere or ‘‘MIN-
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from MIN-O donor tissue [12]. To summarize, the MIN-O
model, in contrast to more commonly used xenograft and cell line
based models, allows experiments to be carried out in immune
intact mice with the transition from DCIS to IBC occurring in
a microenvironment that more closely recapitulates normal disease
progression.
The factors which make the MIN-O model such an attractive
model of DCIS unfortunately present challenges in the area of
transgene expression. As such, there has been limited utility of this
model within the field of molecular imaging where expression of
imaging reporter genes can be exploited to track cells and study
regulation of gene expression in vivo. In vivo imaging studies with
the MIN-O model have to this point been limited to 2-deoxy-2-
[
18F]fluoro-D-glucose (
18FDG) studies that track progression based
on glucose uptake [13,14]. In this manuscript, we present
a protocol for the efficient lentiviral transduction and in vitro
culture of ‘‘MIN-O-spheres’’ and the successful transplantation of
these spheres which ultimately results in propagation of transgenic
MIN-O sublines that retain the in vivo properties of this valuable
model. The primary goal of this work was to incorporate imaging
reporter genes into the MIN-O sublines, thus expanding the reach
of MIN-O based molecular imaging studies into areas which
uncover the mechanisms and molecular events associated with the
progression of DCIS to IBC; however, in a broader sense it is
a method that can be employed to rapidly establish clonal
transgenic lines derived from a wide range of primary cells.
Methods
Ethics Statement
All animal studies were completed in accordance with National
Institutes of Health and Institutional Animal Care and Use
Committee (IACUC) guidelines. The protocol was approved by
the IACUC Committee at the University of California, Davis,
under animal protocol #15927.
Emerald GFP Expression Plasmid
The lentiviral plasmid backbone used for mammalian delivery
in this study is a modified form of pLenti6/TR (Invitrogen).
Briefly, the sequence containing the cytomegalovirus (CMV)
immediate early promoter, b-Globin Intron II and tetracycline
receptor was excised and replaced with a customized multiple
cloning sequence to allow for subcloning of various promoter/
reporter combinations. The EF1a promoter was PCR amplified
and subcloned into the pLenti6 vector using MluI & SalI restriction
sites to create pLenti6/EF1a. Next, emerald green fluorescent
protein (EmGFP; 487 nm/509 nm) was PCR amplified from
pcDNA6.2/EmGFP-miR (Invitrogen) and subcloned into
pLenti6/EF1a using CpoI restriction sites to create pLenti6/
EF1a/EmGFP.
Preparation of Concentrated Lentiviral Particles
293T cells were obtained from ATCC and cultured in
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with
10% fetal bovine serum and 1% penicillin/streptomycin/L-
Glutamine (complete DMEM) and maintained at 37uC in the
presence of 5% CO2 in air. 293T cells were seeded to 15 cm
culture dishes and, at approximately 75% confluency, were co-
transfected with pLenti6/EF1a/EmGFP and the pLP1, pLP2 and
pVSV-G series of viral packaging plasmids (Invitrogen) in a 1:1:1:1
mass ratio. Transfected cells were cultured 48-hours (with a single
medium change at 24-hours post-transfection) and supernatant
containing lentiviral particles was harvested and filtered through
a 0.45 mM acrodisc (PALL Corporation, 4614) to remove cell
debris and residual 293T cells. Lentiviral particles were then
concentrated 100X by centrifugation in 100 kDa Amicon Ultra-15
centrifugal filter units (Millipore, UFC910024) and used immedi-
ately.
Excision of Precancer Lesion and Preparation of Single
Cell Slurry
Excision of all lesions and preparation of single cell slurries were
completed as described previously [12]. Briefly, animals were
anesthetized with nembitol (60 mg/kg) and opened ventrally to
allow for manual removal of precancer lesions. Fatty tissue was
trimmed away and the lesion was washed twice with phosphate
buffered saline (PBS) and manually minced. The minced lesion
was incubated overnight at room temperature in DMEM/F12
media supplemented with BSA fraction V (2%v/v), 5 mg/mL
insulin, 0.5 mg/mL hydrocortisone and 3 mg/mL collagenase
with constant rocking. The following day, digested cells were
subjected to a series of washes, brief trypsinization (0.25 mg/mL
trypsin in the presence of 5 mL DNaseI) and were finally
resuspended in mammary epithelial growth medium [MEGM,
mammary epithelial basal medium supplemented with B27
supplement (5%v/v), epidermal growth factor (20 ng/mL), basic
fibroblast growth factor (20 ng/mL) and Heparin (100 mg/mL)] at
a concentration of 3.75610
5 cells/mL.
Lentiviral Transduction
In a 1.5 mL microcentrifuge tube, 100 mL of the cell slurry
(3.75610
4 cells) were mixed with 150 mL concentrated lentivirus.
This mix was supplemented with 6 mg/mL polybrene (Chemcon,
TR-1003-G) and either centrifuged (30 m/25006g/37uC) or
rocked gently for 30 minutes at RT. Cells were then chilled on
ice for at least five minutes.
Plating and Culture of Cells on MatriGel Layer
During transduction of isolated cells, 200 mL of a 2:1 mix of
Growth Factor Reduced MatriGel (BD Pharmingen) and MEGM
was applied to wells of a 24-well plate which was then incubated at
37uC for 30 minutes to allow for polymerization of the gel matrix.
Following polymerization, 3.5 mL MEGM was mixed with the
cell slurry and this mix was applied to the 24-well plate at 1 mL
(1610
4 cells) per well. Medium was refreshed weekly throughout
the period of in vitro culture.
Plating and Culture of Cells within MatriGel Layer
MatriGel (500 mL) was gently mixed with transduced cells and
aliquots were applied to either 24-well plates (200 mL; 1610
4 cells)
or 96-well thin wall PCR plates (10 mL; ,500 cells). The plates
were then incubated at 37uC for 30 minutes to allow for
polymerization of the gel matrix. Following polymerization, each
well was topped with MEGM (1 mL and 50 mL for the 24- and
96-well plates, respectively) and returned to the incubator.
Medium was refreshed weekly throughout the period of in vitro
culture.
Identification and Transplantation of Transduced Spheres
Individual spheres were counted and assayed for EmGFP
expression using an IX81 inverted fluorescent microscope
(Olympus) and images were acquired using a DP72 12.8 MP
digital camera (Olympus). Spheres from 24-well plates were
identified and transplanted manually with forceps. Spheres from
96-well plates were selected for transplant based both on transgene
expression and the presence of only a single sphere per well. This
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gentle mixing of the entire contents of the well (MEGM and
MatriGel). All transplants were made to pre-cleared 4
th mammary
fat pads.
In vivo Imaging
At selected intervals, animals were anesthetized with 2%
isoflurane and depilatory cream was applied to the general region
surrounding the MIN-O lesion. Depilatory cream was removed
and animals were placed into the Maestro 2 (Caliper Life Sciences)
fluorescent imaging system. For each animal, a monochrome
image was first acquired and then a second fluorescent image
‘‘cube’’ was acquired using a blue excitation filter (430–480 nm)
and image acquisitions running from 500 nm to 720 nm at 10 nm
intervals. This image cube was spectrally unmixed using the
accompanying Maestro 2 software. Images presented here are
comprised of the unmixed composite image overlaid on the
corresponding monochrome image using ImageJ software [15].
Immunohistochemistry
Four micron sections were prepared from excised MIN-O
lesions and either stained with Mayer’s hematoxylin and eosin
(H&E) stain or probed with goat a-GFP (1:800; Abcam; ab6673)
followed by horse a-goat (1:1000; Vector; BA-9500) to detect
EmGFP protein expression.
Quantitative Real Time PCR
EmGFP negative and positive regions were identified by IHC
within excised lesions and isolated via laser capture. Genomic
DNA was purified from isolated tissue using the DNAeasy
purification kit (Qiagen) and subjected to quantitative real time
PCR (qPCR) analysis on an iCycler IQ5 (BioRad) using the
following primer pairs:
EmGFP 126–310: 59-CCATCTTCTTCAAGGACGAC-39
59-GGCTGTTGTAGTTGTACTCC-39
PyVmT 825–973: 59-GACGAAATCCTTGTGTTGCT-39
59-ATGTCCAAATACAGATCCTCCA-39
GAPDH: 59-TCAAGATCATCAGCAATGCCT-39
59-ATCACGCCACAGTTTCCC-39
Mean Ct values were obtained and subjected to PFAFFL
scoring [16] with GAPDH serving as the reference gene.
Results
Transduction and in vitro Culture of Isolated Single Cells
In order to optimize the in vitro portion of our protocol, two
methods of culture were utilized. In the first method, spheres were
cultured on a layer of MatriGel that was allowed to polymerize in
24-well plates prior to addition of the transduced cell slurry. In the
second method, transduced cells were added to MatriGel prior to
plating which allowed for sphere culture within the MatriGel
layer. In vitro culture of spheres using the second method was
completed in 24-well plates and 96-well thin wall PCR plates with
similar results relative to sphere formation and transduction
efficiency.
Approximately four days following plating, early sphere de-
velopment was evident regardless of culture method. Also at this
time, the presence or absence of EmGFP was readily detected in
transduced spheres. Although transduction efficiency was rarely
less than 40–50%, this figure varied significantly over the course of
our studies with a maximum of ,80% achieved with no significant
differences observed between samples subjected to ‘‘spinduction’’
or gentle rocking at RT. Approximately one in 650 isolated single
cells formed a sphere in vitro when embedded within the MatriGel
layer. This is a marked improvement when compared to culture
on top of MatriGel which yielded one sphere per approximately
3000 cells. In addition to the increase in sphere formation, sphere
morphology was also heavily influenced by culture conditions.
Although culture both on top of and within the MatriGel layer
yielded multiple sphere types, the relative abundance of various
forms was highly dependent upon culture conditions. Following
culture on MatriGel, most spheres (.90%) maintained spherical
integrity and had what appeared to be a solid core (Figure 1a).
However, spheres cultured within MatriGel most frequently
displayed a hollow morphology with single sites of irregularity
(Figure 1b & 1c). The solid core morphology was never observed
in spheres cultured within MatriGel. Additionally, sphere
morphology appears to predict growth in vivo. The frequency of
lesions following transplantation of hollow spheres is typically
between 40–80% with variance likely due to the technical
challenge of transplantation. Conversely, spheres displaying the
solid core morphology have not produced lesions in vivo following
transplantation (n=20).
Transplantation of Single Spheres into FVB Mice
The results presented in the remainder of this manuscript will
focus on spheres cultured within the MatriGel layer in 96-well
PCR plates. In our experience, this method is the most efficient
and least technically challenging of the three methods we have
employed. As mentioned previously, in vitro culture on MatriGel
has not been a successful method of generating spheres suitable for
transplantation and in vivo propagation. Although we have
successfully transplanted spheres cultured within MatriGel in 24-
well plates, that method has proven to be highly inefficient due to
the technical difficulty of excising only a single sphere and
correctly transplanting it into the pre-cleared fat pad.
First Generation MIN-O-D/EmGFP Transplant Line
Following 14 days of in vitro culture, the entire contents of five
wells (MatriGel and MEBM; ,40 mL), each identified to have
a single EmGFP positive sphere, were individually transplanted via
syringe into pre-cleared 4
th mammary fat pads of three FVB mice
(bilateral transplants in two mice and a single transplant in the
third). By four weeks post-transplant, all five transplants produced
lesions; however, the EmGFP signal generated by these lesions was
highly variable and in some instances not detectable in vivo. Of the
five lesions, one in particular displayed a high level of EmGFP
signaling in vivo (Figures 2a & 2b) and was selected for in vivo
passage and maintenance. In addition to EmGFP expression,
preservation of the characteristics of the MIN-O model was vital.
In order to examine this, a portion of the excised lesion was
reserved for histologic analysis and immunohistochemistry (IHC).
The histology shows MINO morphology characterized by
a leading edge of growth into the fat pad stroma, differentiation
with basal and luminal epithelial layers in cords and ductules
surrounded by remodeled host stroma and increased fat pad
vascularity. Progression to central areas of dedifferentiation and
proliferation associated with the invasive carcinoma phenotype
was also observed. In sum, the morphology and progression was
identical to the parent precancer lesion (Figures 3a–d).
In vivo Passage of MIN-O/EmGFP
As the objective of this study is the maintenance of an EmGFP
positive subline in vivo, a portion of the lesion was disaggregated
and a cell slurry was prepared using the remaining portion of the
lesion and injected into the pre-cleared fat pad of another FVB
mouse. This cycle of excision, dissociation and injection was
repeated three times to generate second, third and fourth
Lentiviral Transduction of MIN-O
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lesion was reserved for IHC analysis.
Second Generation MIN-O-D/EmGFP
At 28 days post-injection of cells isolated from the first
generation lesion, the resulting second generation lesion was
imaged in vivo. As expected, the lesion retained EmGFP expression
which was readily detectable (Figure 4a). However, IHC analysis
showed that, unlike the first generation lesion, there were small
regions of EmGFP negative cells (Figure 4b). These regions
included areas in which EmGFP expression was nearly completely
lost (Figure 4c) and heterogeneous areas in which EmGFP positive
and negative cells were interspersed (Figure 4d).
Third and Fourth Generation MIN-O-D/EmGFP
As in both earlier passages, the third and fourth generation
MIN-O-D/EmGFP lesions were easily detected with in vivo
fluorescent imaging (Figures 5a & 5b). Consistent with the IHC
results from the second generation lesion, however, a pattern of
progressive EmGFP loss was evident in the third and fourth
generation lesions (Figures 5c through 5f). Again, this loss
presented as regions of complete loss and regions of partial loss.
This culminated in massive loss of EmGFP expression in the
fourth generation lesion.
Generational Loss of EmGFP Expression
In order to determine whether loss of EmGFP expression was
due to silencing or genomic loss of the lentivirally delivered
EmGFP expression cassette, genomic DNA from EmGFP positive
and negative regions (isolated via laser capture) was subjected to
qPCR analysis using primers for EmGFP and PyVmT. As the
MIN-O transplant lines were originally derived from FVB/
PyVmT mice, PyVmT is the only known genomic difference
between MIN-O-derived tissue and tissue from the otherwise
genetically identical FVB host mouse. qPCR analysis of PyVmT in
this assay thus confirms whether EmGFP negative tissue is MIN-
Figure 1. In vitro culture of MIN-O-spheres. MIN-O-spheres cultured from single cell slurries of MIN-O Line D grown either on MatriGel in a 24-
well plate (a), within the MatriGel layer in a 24-well plate (b) or within the MatriGel layer in a 96-well PCR plate (c). All images are 200X magnification
with bright field images shown on the left, corresponding FITC-filtered images in the middle and overlaid images on the right and were captured
14 days post-transduction and plating. While the sphere shown in 1a failed to proliferate following transplantation, both spheres shown in 1b & 1c
yielded EmGFP positive lesions in vivo.
doi:10.1371/journal.pone.0039350.g001
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that, while there is no significant difference in the abundance of
PyVmT in EmGFP positive and negative regions, sequence
encoding EmGFP is nearly absent (0.18% that of EmGFP positive
tissue) in EmGFP negative tissue (Figure 6e). Two conclusions can
be drawn from these data. First, tissue from both EmGFP positive
and negative areas is predominantly MIN-O in origin (as indicated
by the similar prevalence of PyVmT in isolated samples). Second,
the dominant mode of observed EmGFP loss is expulsion of the
lentivirally delivered expression cassette from the genome rather
than gene silencing (as indicated by the absence of EmGFP coding
sequence in the genomic DNA of EmGFP negative tissue).
Figure 2. In vivo and ex vivo images of first generation MIN-O Line D/EmGFP subline. a) Spectrally unmixed image overlaid on the
corresponding monochrome image showing the presence of an EmGFP positive lesion in the general region of the 4
th right mammary fat pad. b) Ex
vivo validation of in vivo image confirming the source of the EmGFP signal to be the lesion excised from the 4
th right mammary fat pad (right). For
comparison, an EmGFP-negative lesion is shown on the left. Both images were acquired 27 days post-transplant.
doi:10.1371/journal.pone.0039350.g002
Figure 3. Immunohistochemical analysis of excised MIN-O Line D/EmGFP lesion. Four micron sections of first generation MIN-O/EmGFP
lesion either stained with Mayer’s H & E (a&b) or probed with a-GFP in order to asses distribution of EmGFP within the lesion (c&d). Evident in the IHC
are morphological characteristics common to the parental MIN-O transplant line which include growth into the fat pad stroma, basal and luminal
differentiation, remodeled stroma and increased vascularity (arrow). Analysis of EmGFP expression reveals a high degree of homogeneity throughout
the MIN-O tissue (arrow), but not in the host-derived stroma (arrowhead).
doi:10.1371/journal.pone.0039350.g003
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The protocol presented here allows for the development of
clonally derived sublines of the MIN-O transplant lines in-
corporating imaging reporter genes. Prior to this work, non-
invasive imaging of this series of lines was limited to studies with
administered contrast agents (radioactive or fluorescent) due to an
inability to make the type of genomic modifications commonly
employed in cell line and xenograft studies. This advance in
technology makes possible more sophisticated studies designed to
integrate the potential of non-invasive imaging and the biological
relevance of MIN-O to elucidate the events involved in pro-
gression of DCIS to invasive carcinoma. In addition to the
fluorescent reporter construct used here as proof of principle,
lentiviral transduction can be readily exploited to deliver a more
complex payload such as gene knockdown and overexpression
cassettes and/or allele replacement as well as promoter-specific
and pathway dependent reporters. The fact that novel sublines are
clonal in lineage also allows for greater consistency and clarity of
results relative to studies utilizing ‘‘mixed pools’’ of transduced
cells.
Figure 4. In vivo image and immunohistochemical analysis of second generation MIN-O Line D/EmGFP lesion. a) Spectrally unmixed
image overlaid on the corresponding monochrome image showing the presence of an EmGFP positive lesion in the general region of the 4
th right
mammary fat pad. Image was acquired 29 days post-transplant. b) Immunohistochemical analysis of second generation lesion reveals strong general
EmGFP expression, but also EmGFP-negative regions. c) Enlarged section of 4b showing a high degree of segregation of EmGFP-positive (upper right)
and EmGFP-negative (lower left) cells. d) Enlarged section of 4b showing interspersed EmGFP-positive and EmGFP-negative cells. Arrows show
EmGFP positive basal cells and arrowheads show EmGFP positive luminal cells.
doi:10.1371/journal.pone.0039350.g004
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mixed pool lines regardless of the cell origin or method of
development, we have found that one of the primary advantages of
this protocol is the low number of cells required. In the MIN-O
model presented here, less than 50,000 cells are required for the
plating of a 96-well PCR plate. A single plate yields approximately
12–18 transplantable wells; that is, wells in which only a single
fluorescent sphere developed. This was particularly significant
within the context of the MIN-O model due to the inability to
allow lesions to progress beyond the precancer stage and the
resulting decrease in the yield of primary cells per mouse. Given
the difficulty and cost associated with culture of many other types
of primary cells, we expect this feature of our protocol to be
attractive to researchers in need of similarly engineered lines.
Interestingly, sphere morphology is highly predictive of sphere
growth in vivo. This suggests that there are different types of
progenitor cells in the MIN-O, with different biologic potential for
differentiation and growth in vivo. It is well known that many cell
types from the mouse mammary gland show divergent differen-
tiation and growth depending on the culture conditions. In most
examples, however, the ‘‘on top’’ versus ‘‘in’’ MatriGel compar-
isons are equal [17]. In our experiments here, we found that
culture within MatriGel favored the transplantable hollow
phenotype over the non-transplantable solid core phenotype.
While the precise differences between the two culture methods
that contribute to differences in sphere morphology are not
known, the critical issue within the context of this study is that
culture within MatriGel improves the efficiency of developing
transplantable MIN-O spheres. Further evaluation of the factors
responsible for this increase in efficiency may be important to
cancer stem cell differentiation and biology.
Not surprisingly, the primary drawback to serial transplant of
genetically engineered cells is the gradual loss of transgene
expression with increasing generations. Loss of transgene expres-
sion regardless of the mode (i.e., methylation, deletion, loss of
heterozygosity, etc.) has been widely accepted as a pitfall of
genetically engineered cells. The rate of loss of expression can be
highly dependent upon selective pressures (immunogenicity,
changes in proliferative rates, etc.) if a given expression cassette
and expressed proteins confer negative selection. Even if there is
no significant negative selection, transgenes can still be removed or
silenced spontanesously. This difficulty is overcome in vitro by the
maintenance of selective pressure via supplementation of growth
media with antibiotics for which resistance is genetically linked to
transgene expression. Unfortunately, this approach is not easily
achieved within the context of the MIN-O model as the main
advantage of this transplant line is that, with the exception of
PyVmT and the transgene, MIN-O cells are genetically identical
to the host mouse. Fortunately, the utility of the fluorescent
reporter during in vitro screening can be extended to allow for
fluorescence-activated cell sorting (FACS) of cells isolated from
precancer lesions in order to enrich for cells in which the transgene
remains expressed. In our experience in unrelated projects, we
have found that FACS has little or no negative effect on cell
viability and lesion formation. Sorting can in theory be completed
immediately prior to injection of study cohort(s) to ensure uniform
transgene expression as our observations have shown high stability
of expression throughout the period of a single generation. Given
Figure 5. In vivo images and immunohistochemical analysis of third and fourth generation MIN-O Line D/EmGFP lesions. a&d )
Spectrally unmixed image overlaid on the corresponding monochrome image showing the presence of a GFP positive lesions in the general region of
the 4
th right mammary fat pad of third (a) and fourth (d) generation MIN-O Line D/EmGFP. Images were acquired 33 and 29 days post-transplant,
respectively. b) Immunohistochemical analysis of third generation lesion reveals weakened general GFP expression as well as several GFP-negative
regions. e) Similar analysis of fourth generation lesion reveals large regions of GFP-negative cells. c & f) Enlarged sections of 5b and 5f, respectively.
Arrows show EmGFP positive basal cells and arrowheads show EmGFP positive luminal cells.
doi:10.1371/journal.pone.0039350.g005
Figure 6. Quantitative Real-Time PCR Analysis of Genomic EmGFP and PyVmT Sequence in Laser Captured EmGFP Positive and
Negative Regions. a-d) Images acquired during laser capture of MIN-O tissue shows EmGFP negative regions before (a) and after (b) dissection and
EmGFP positive regions before (c) and after (d) dissection. e) qPCR analysis of EmGFP and PyVmT sequence in genomic DNA isolated from laser
captured sections. Calculated PFAFFL values were averaged for each primer pair and normalized (EmGFP positive tissue =100), allowing for direct
comparison of the percent relative abundance of EmGFP and PyVmT sequence in designated samples. While genomic DNA from EmGFP negative
tissue shows significant loss of EmGFP coding sequence, a similar decrease in sequence encoding PyVmT was not observed. These data indicate that,
while the majority of tissue in both regions is MIN-O in origin, the EmGFP expression cassette has been largely expelled from the genome of EmGFP
negative cells.
doi:10.1371/journal.pone.0039350.g006
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of genetic material and the toxicity or immunogenicity of
expressed proteins, potential loss of expression should be
considered prior to in vivo propagation. As a related side note, it
is also worth noting that we achieved stable EmGFP expression
through a single generation only when the elongation factor 1a
(EF1a) promoter was used to drive its expression. We completed
several iterations of this protocol using lentiviral particles
generated with the pLenti6/CMV/EmGFP plasmid and, al-
though similar results were observed in vitro with respect to sphere
morphology, transduction efficiency and transgene expression,
outgrowths following transplantation were consistently EmGFP-
negative indicating ‘‘silencing’’ of the CMV promoter as has been
reported extensively [18,19,20].
As our understanding of the role microenvironment plays in
both normal and atypical development increases, so too will the
emphasis placed on the development and utilization of models
such as MIN-O which more closely recapitulate the natural
processes being queried. As described here, the period from
excised unmodified tissue to in vivo imaging of genetically modified
lesions which are clonal in lineage is approximately 6 weeks. The
transduction efficiency of primary cells, notorious for their
difficulty to transfect or transduce, is only slightly lower than
what is typically achieved in robust cell lines in vitro. Because of
both of these factors we believe this method of genomic
modification of primary cells to be a powerful tool for researchers
which will expand the use of complex animal models into areas
such as in vivo molecular imaging which have been previously
largely restricted to studies employing xenografts and cell lines.
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